Credit: Shutterstock photoSienna Biopharmaceuticals, a clinical-stage biotech developing topical therapies for dermatological conditions, raised $65 million by offering 4.3 million shares at $15, the midpoint of the range of $14 to $16. Insiders had indicated an interest in buying up to $25 million on the IPO, representing 38.5% of the deal. Sienna Biopharmaceuticals plans to list on the Nasdaq under the symbol SNNA. J.P. Morgan and Cowen & Company acted as lead managers on the deal.
The article Sienna Biopharmaceuticals prices IPO at $15 midpoint originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
